학술논문
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Document Type
Artikel
Author
Facon, T; Kumar, SK; Plesner, T; Orlowski, RZ; Moreau, P; Bahlis, N; Basu, S; Nahi, H; Hulin, C; Quach, H; Goldschmidt, H; O'Dwyer, M; Perrot, A; Venner, CP; Weisel, K; Mace, JR; Raje, N; Tiab, M; Macro, M; Frenzel, L; Leleu, X; Ahmadi, T; Wang, JP; Van Rampelbergh, R; Uhlar, CM; Tromp, B; Delioukina, M; Vermeulen, J; Usmani, SZ
Source
The Lancet. Oncology. 22(11):1582-1596
Subject
Language
English
English
English
ISSN
1474-5488